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Abstract 
Rationale: Hypothalamic-pituitary-adrenal axis dysregulation predicts poor clinical 
and biochemical response to antidepressants.  Antiglucocorticoids have therapeutic 
benefits but most have a troublesome adverse event profile. Aspects of 
neuropsychological performance, notably working memory, are susceptible to 
corticosteroid modulation and are impaired in depression. Aspirin has been shown to 
attenuate the adrenocorticotropic-hormone and cortisol response to physiological 
challenge suggesting its potential to act as an augmenting agent in depression.  
Objectives: To examine the effect of sub-acute (300mg daily for 7 days) aspirin pre-
treatment on the cortisol awakening response and the effect of acute (600mg) and sub-
acute aspirin on the neuroendocrine and neuropsychological response to the arginine 
vasopressin analogue, desmopressin.  
Results: We demonstrated that aspirin pre-treatment did not attenuate the cortisol or 
ACTH response to desmopressin but, as hypothesised, significantly reduced the 
cortisol awakening response and improved working memory. 
Conclusions: Further studies to examine the impact of aspirin on neuropsychological 
performance and HPA axis function are warranted. 
Key Words 
Cortisol, ACTH, adrenocorticotropic hormone, arginine vasopressin, 
neuropsychological, digit span,  
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Introduction 
This aim of this study was to investigate whether aspirin has potential as an 
augmenting agent in major depressive disorder (MDD). MDD is a huge global 
problem (Murray and Lopez 1997) in part because of the high rates of treatment 
resistance.  
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is a common 
concomitant of MDD and is associated with treatment non-response (Young et al. 
2004b), most likely via an attenuation of the serotonergic response to antidepressants 
(Gartside et al. 2003). Normalisation of the HPA axis may precede and be necessary 
for treatment response (Ising et al. 2007). A recent Cochrane review supports the 
proposition that agents that reduce HPA axis overactivity have efficacy as augmenting 
agents in the treatment of MDD (Gallagher et al. 2008).  
Working memory impairment has been demonstrated in mood disorders including 
drug free depressed patients (Porter et al. 2003) and unipolar and bipolar patients who 
are in symptomatic recovery (Robinson et al. 2006; Zobel et al. 2004). The severity of 
the impairment appears to relate to the degree of HPA axis dysregulation (Watson et 
al. 2006). Corticosteroid administration impacts on neuropsychological performance 
(Lupien and McEwen 1997; Young et al. 1999).including declarative memory 
(Newcomer et al. 1994); working memory, however, appears to be particularly 
sensitive(Lupien et al. 1999). Working memory has utility as an outcome measure of 
treatment trials in mood disorder patients (Venn et al. 2005; Young et al. 2004a). 
Aspirin has been shown to reduce the HPA axis response to physiological and 
pharmacological challenge. For instance Nye and colleagues have shown that acute 
administration of aspirin reduces the ACTH and cortisol response to arginine 
vasopressin (AVP) (Nye et al. 1997). 
We hypothesised that both acute and sub-chronic aspirin treatment would reduce the 
adrenocorticotropic hormone, cortisol and working memory response to an analogue 
of arginine vasopressin and would attenuate the cortisol awakening response (CAR). 
Methods 
The study had Ethics Committee Approval and all subjects gave informed consent.  
Subjects were given placebo (for 7 days), acute aspirin (placebo for 6 days then 
600mg aspirin on day 7) and chronic aspirin (300mg for 7 days) with a washout 
period of 2 weeks between regimes in a random order (unstratified 6 block 
randomisation was used). Medication was taken at 10am.  
On the test day, patients were asked to produce a passive drool saliva sample into a 
plastic container on waking and at 15 minute intervals for a further hour, whilst 
fasting. They then took their final drug treatment at 10 am (in the acute aspirin arm, 
subjects had therefore taken only placebo for 6 days and the acute aspirin samples 
were not included in the CAR analysis). Subjects attended the laboratory at noon, 
where they had a standard light lunch and were canulated. At 1400h (time 0), 10µgs 
of desmopressin (ddAVP) was injected intravenously over 15 seconds. Blood samples 
were taken at -30,-15, 0, 15, 30, 45, 60, 75 and 90 minutes. Samples were centrifuged, 
stored at -80 C and assayed for cortisol in-house by using corti-cote 
radioimmunoassay kits (ICN Pharmaceuticals,California, USA). For salivary cortisol, 
the inter-assay and intra-assay coefficients of variation (CV) for the low (4.5 nmol/l), 
4 
 
medium (16.2 nmol/l) and high (66.4 nmol/l) quality controls were 10.8%, 10.5%, 
7.4% and 16.4%, 10.7%, 13.0%, respectively. The corresponding values for the 
plasma cortisol analysis were 5.4%, 9.7%.10.9% and 10.9%, 9.4%. 10.8%. Samples 
were also assayed in house for ACTH, intra and inter assay CVs were 25.1% and 
7.9%.  
Neuropsychological performance was determined at 1500h. Alternative versions of 
the following tests were used on each visit: 
The Wechsler digit span (Wechsler 1981). In this task, subjects are asked to recall 
a string of digits, first forwards and then reversed.  
The Rey-Auditory Verbal Learning Test (Rey-AVLT) (Rey 1964). This is a test 
of immediate and delayed verbal learning. Subjects are presented with a list of 15 
words a total of five times, with immediate recall tested after each occasion (list 
A1–A5). A distracter list (list B) is then presented, again with an immediate recall 
test. Without further presentation, recall of list A is then tested immediately and 
again after a filled delay of 30 minutes (list A7). Finally, recognition of both lists 
is tested from among a series of distracters. For each measure, the number of 
words correct is recorded. 
The Controlled Oral Word Association Test (Benton's FAS) (Benton and 
Hamsher 1976). This is a verbal fluency test in which subjects generate words 
beginning with a particular letter following a prescribed set of rules. Total 
number of words correct is recorded. 
Digit Symbol Substitution Test (DSST)(Wechsler 1981). A test of attention and 
psychomotor speed. 
Analysis 
Thirteen healthy male subjects were recruited by local advertisement for this double-
blind, placebo-controlled, crossover study design. Subjects in the analysis had a mean 
age of 27.6 (SD=6.2), had spent 17.2 years in full time education (SD=2.3), drank 
13.6 (SD=9.7) units of alcohol per week and had a mean national association reading 
test (NART) of 116, (SD =7.6) 
Area under the curve was measured by trapezoid integration, with subtraction of 
baseline cortisol secretion. Statistical analysis employed repeated measures analysis of 
variance (ANOVA; all within subject factors) and paired t tests (two-tailed). All 
analysis was performed with SPSS version 15. In the ANOVA, significance is 
reported by Huynh-Feldt corrected P values and uncorrected degrees of freedom are 
reported for clarity. 
Results 
ddAVP was tolerated and no side effects were reported. For the final data analysis, 
two subjects were excluded after plasma analysis revealed detectable salicylate during 
the placebo arm.  
The CAR AUC was significantly attenuated after chronic aspirin treatment 
(mean=22.1; SD. = 239.8) compared with placebo (mean=171.3 nmol.min/l; SD. = 
163.6; mean difference = 149.1; SD.=154.6; 95%CI of the difference = 45.3 to 253.0; 
t=3.2, df=10, P=0.01 fig I). In the acute aspirin arm (in which subjects had received 
only placebo) the CAR AUC had a mean of 57.5 with a standard deviation of 234.2 
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and did not differ from the CAR AUC after chronic aspirin treatment (t=0.43; df=10; 
P=0.67). 
Repeated measures ANOVA of the CAR using “drug” (placebo and chronic aspirin) 
and “time” showed a significant effect of drug (F=8.5, df=1,10; P=0.015) but only an 
effect of time (F=2.9; df=4,40; P=0.063) and drug by time (F=2.6; df=4,40; P=0.071) 
at the trend level. Repeating this analysis using3 levels of “drug” (placebo, acute and 
chronic aspirin) revealed an effect of time (F=3.7; df=4,40; P=0.025) but not drug 
(F=2.1, df=2,20, P=0.15) or drug by time (F=1.4; df=8,80; P=0.23).  
Repeated measures ANOVA using 3 levels of “drug” (placebo, acute and chronic 
aspirin) and time revealed  a significant effect of time (cortisol, F=6.9, df= 8,80, 
P<0.0005; ACTH, F=5.3, df=8,80, P=0.001) but no drug by time effect on the plasma 
cortisol (F 0.57, df =16,160, P=0.82), or ACTH (F=0.548, df =16,160, P=0.79), 
response to ddAVP (figs II and III). In the placebo arm, there was a significant 
increase in plasma cortisol (t=2.3; df=10; P=0.04) and plasma ACTH (t=3.7; df=10; 
P=0.004) between the 1515 sample and the 1500h sample (taken immediately prior to 
ddAVP administration.  
Backwards digit span differed significantly between the 3 pre-treatment groups 
(FigIV; F=4.5; df =2, 20; p=0.025). Post hoc analysis revealed that backwards digit 
span was significantly greater after chronic (t=2.5; df=10; P=0.03) but not after acute 
(t=1.5; df=10; P=0.17) aspirin treatment (compared with placebo).  
Forward digit span, the Rey AVLT measures, DSST and verbal fluency did not differ 
between treatment arms (P>.19, figure IV). 
Discussion 
The hypothesised attenuation of the cortisol response to ddAVP was not seen, 
however, the study demonstrated that aspirin treatment over 6 days attenuated CAR 
AUC.  
There was an effect of aspirin treatment on the task of working memory (digit span 
backwards) that was not seen on the control measures of executive function (verbal 
fluency) or declarative memory (Rey-AVLT).  
The demonstration of salicylates in the blood of two subjects in the placebo arm 
reduced the effective sample size to 11, limiting the power of the study. 
The impact of salicylates on ACTH and cortisol release in previous studies varies 
depending on a number of factors, including dose. For example, levels of over 25 
microgrammes /mL but not 10 microgrammes /mL attenuated the cortisol response to 
castration in calves (Coetzee et al. 2007). The nature of the challenge also appeared 
relevant- in studies using hypoglycaemic and naloxone stimulation, salicylates tended 
not to reduce cortisol release (Cavagnini et al. 1979; Halter and Metz 1982; Hockings 
et al. 1993). Duration of treatment also appears important, 10 days treatment with 1.6 
grams of aspirin daily reduced the cortisol response to exercise (Di Luigi et al. 2001), 
whereas in a different study, 1.5 grams daily over 2 days did not (Przybyłowski et al. 
2003) 
The effect of aspirin on CAR but not on the cortisol or ACTH response to ddAVP is 
intriguing, particularly given the previously demonstrated impact of aspirin on the 
ACTH and cortisol response to AVP (Nye et al. 1997). The absence of a ddAVP 
effect may be a type II error consequent on a lack of power. Pharmacological 
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differences between ddAVP and AVP may also be important. ddAVP is an analogue 
of AVP used in this study because of its better safety and tolerability profile but 
limited by its comparatively reduced affinity for the AVP1b receptor. There was a 
cortisol and ACTH response to ddAVP, however, had we used AVP instead, the 
response may have been greater allowing any influence of aspirin on the HPA axis to 
be revealed.  
Aspirin may have exerted the effect on CAR by chronic lowering of inflammatory 
cytokines (von Känel et al. 2008) thereby enhancing GR function (Pace et al. 2007) 
and hence negative feedback control of cortisol release. AVP treatment has been 
shown to synergise the effect of CRH on pituitary corticotrophs and overcome the 
suppressant effects of GR activation on ACTH release(von Bardeleben et al. 1985).  
Administration of ddAVP may have therefore minimized the influence of GR 
function on ACTH release and hence negated the aspirin effect. 
The results are promising and suggest that further studies to evaluate the effect of 
aspirin on HPA axis function and neuropsychological performance are warranted. 
These will allow examination of the potential for a therapeutic trial of aspirin in 
patients with MDD or mild cognitive impairment, 
Legends 
Figure I Mean increase in salivary cortisol awakening response in subjects treated 
with chronic aspirin compared with those receiving placebo Error bars show standard 
error of the mean. 
Figure II Effect of aspirin pre-treatment on the ACTH response to desmopressin 
(administered at 1500h). Error bars show standard error of the mean.  
Figure III Effect of aspirin pre-treatment on the cortisol response to desmopressin 
(administered at 1500h). Error bars show standard error of the mean.  
Figure IV. Effect of aspirin pre-treatment on digit span backwards span. Error bars 
show standard error of the mean  
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Figure IV 
Neuropsychological Data 
Neuropsychological 
Variables 
Acute aspirin 
Mean (SD) 
Chronic aspirin 
Mean (SD) 
Placebo 
Mean (SD) 
Digit span    
Forward span 7.8(1.2) 7.7(1.3) 8.0(1.3) 
Backwards span 6.8(1.3) 7.3(1.1) 6.5(1.3) 
Rey-AVLT    
Learning (total A1 to 5) 52.6(9.2) 53.4(12.8) 56.4(13.0) 
Long term recall (A7, % 
retained) 82.7(18.0) 82.2(18.9) 93.1(33.5) 
Long-term recognition (list 
A) 13.2(2.1) 12.9(2.2) 13.8(1.8) 
Verbal fluency (FAS)    
Number correct 48.6(7.0) 46.4(8.4) 49.9(11.2) 
DSST    
Number correct in 90 
seconds 66.2 66.4 63.8 
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